Ario Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.20 M
- Revenue Growth 346.88%
- Profit Growth 290.18%
- Ebitda 379.34%
- Net Worth 296.45%
- Total Assets 89.48%
About Ario Pharma
Ario Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 March 2018 (Six years and 11 months 7 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.20 M.
Archis Nerlikar and Bhavna Nerlikar serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24304MH2018PTC306090
-
Company No.
306090
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Mar 2018
-
Date of AGM
28 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ario Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Archis Nerlikar
|
Director | 08-Mar-2018 | Current |
|
Bhavna Nerlikar
|
Director | 27-Mar-2020 | Current |
Financial Performance of Ario Pharma.
Ario Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 346.88% increase. The company also saw a substantial improvement in profitability, with a 290.18% increase in profit. The company's net worth Soared by an impressive increase of 296.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ario Pharma?
In 2022, Ario Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nerlikar Hospitals Private LimitedArchis Nerlikar and Bhavna Nerlikar are mutual person
Charges (Loans)
₹2.20 M
₹0
Charges Breakdown by Lending Institutions
- Tata Capital Housing Finance Limited : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Jun 2022 | Tata Capital Housing Finance Limited | ₹2.20 M | Open |
How Many Employees Work at Ario Pharma?
Unlock and access historical data on people associated with Ario Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ario Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ario Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
